Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963805 | 0.82 | BACE1 (0.35) | BACE1CYP2A6KDM4EMAPTALDH1A1 | |
| SCHEMBL25251144 | 0.77 | DGAT1 (0.35) | BACE1CYP2A6KDM4EMAPTALDH1A1 | |
| SCHEMBL2119502 | 0.77 | CCR1 (0.46) | CYP2A6MAPTKMT2AMEN1RAB9A | |
| SCHEMBL26650555 | 0.77 | EGFR (0.33) | BACE1CYP2A6EGFRKDM4EMAPT | |
| SCHEMBL30748588 | 0.77 | EGFR (0.33) | BACE1CYP2A6EGFRKDM4EMAPT | |
| SCHEMBL7264434 | 0.77 | NQO2 (0.44) | BACE1CYP2A6EGFRKDM4EMAPT | |
| SCHEMBL25911523 | 0.77 | ESR1 (0.42) | GAA | |
| SCHEMBL20660798 | 0.74 | BACE1 (0.33) | BACE1CYP2A6EGFRKDM4EMAPT | |
| SCHEMBL31623199 | 0.73 | POLB (0.34) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL1964184 | 0.73 | PDE10A (0.30) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197374-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2025-06-19 | — | — | US | disclosed |
| EP-4547658-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119325469-A | WEE1 degrading compounds and uses thereof | 百时美施贵宝公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-2346830-B1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2346830-B1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2346830-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck Sharp & Dohme Corp. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2010030722-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GCGR, GLP1R, GPR119 | BACE1 2112/4885CYP2A6 1336/4885NT5E 1359/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | BACE1 2266/4885CYP2A6 3665/4885NT5E 3021/4885 |
| US-20250197374-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | WEE1, WEE2, PPME1 | BACE1 2266/4885CYP2A6 3665/4885NT5E 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.